MRI-guided optimisation of neoadjuvant chemotherapy duration was associated with favourable 3-year event-free survival outcomes in patients with stage II–III HER2-positive breast cancer. This approach represents a novel strategy that reduces treatment burden, minimises toxicity, and preserves quality of life in a subset of patients with early HER2-positive breast cancer.
[Articles] MRI-based personalisation of neoadjuvant chemotherapy duration in HER2-positive early breast cancer (TRAIN-3): primary results from a multicentre, single-arm, phase 2 study
The Lancet Oncology | | Fleur M Louis, Anna van der Voort, Mette S van Ramshorst, Antonios Daletzakis, Ingrid A Mandjes, Inge Kemper, Mariette J Agterof, Wim A van der Steeg, Joan B Heijns, Marlies L van Bekkum, Ester J M Siemerink, Philomeen M Kuijer, Astrid Scholten, Jelle Wesseling, Marie-Jeanne T F D Vrancken Peeters, Mees D Egeler, Lonneke V van de Poll-Franse, Ritse M Mann, Gabe S Sonke, Dutch Breast Cancer Research Group (BOOG)
Topics: breast-cancer, chemotherapy, clinical-trials, research